rendering integrity and monitoring
Use the official inequality and formulation-specific sample timing
The mirror loses the severe-PK inequality sign; the official text prints <=29 mL/min/1.73 m2. The single-dose renal study is not a renal dosing ladder.
What to reconcileUse the separately attributed official finding. Confirm PROCYSBI, assay and 12-hour trough timing; do not substitute CYSTAGON sampling.
2 source identities and dates
GlobalRPh RX List - PROCYSBIGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
PROCYSBI delayed-release oral cysteamine for nephropathic cystinosis; immediate-release CYSTAGON is a separate product.
Read this stored source Cysteamine - PROCYSBI delayed-release capsules and granulesDailyMed | Source revision: 12/2024
PROCYSBI delayed-release oral cysteamine for nephropathic cystinosis; immediate-release CYSTAGON is a separate product.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.9.
source scope and renal guidance
Capsule NVAF guidance is not the pellet or VTE regimen
The current capsule label supplies the adult NVAF renal regimen; the retrieved generic-title RX page describes pediatric pellets. VTE and interaction restrictions differ.
What to reconcileChoose exact formulation and indication before interpreting renal thresholds.
1 source identities and dates
PRADAXA capsules - official adult NVAF renal guidanceNational Library of Medicine / manufacturer labeling | Source revision: Official label updated 2025-06-25; full revision date not separately established
PRADAXA oral capsules: adult nonvalvular AF only. Separate from pediatric oral pellets and VTE regimens.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v6.1.
source scope and renal guidance
PRADAXA mirror is a pediatric pellet page
The generic-title RX page contains pellet dosing text using Schwartz eGFR, including an unresolved exact-50 boundary. It is not the adult NVAF capsule protocol.
What to reconcileNo pediatric dose is supplied; confirm the current pellet label before prescribing.
1 source identities and dates
GlobalRPh RX List - PRADAXA oral pelletsGlobalRPh-hosted RX List | Source revision: November 2023 (mirror)
PRADAXA oral pellets: pediatric renal subsection only. Capsule description elsewhere in the mirror is not reconciled with the pellet dosing sections.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v6.1.
source scope and renal guidance
Indication, initiation and continuation are separate
The older mirror and June 2026 label retain different thresholds for glycemic and other adult indications. The official surgery paragraph no longer limits its wording to major surgery.
What to reconcileUse the newer source wording within its scope; a continuation statement below 25 is not a general initiation/dialysis rule.
2 source identities and dates
GlobalRPh RX List - FARXIGAGlobalRPh-hosted RX List | Source revision: June 2024 (mirror)
FARXIGA: adult glycemic versus cardiorenal indications, not a common threshold for all SGLT2 inhibitors.
Read this stored source FARXIGA - official indication-specific renal guidanceNational Library of Medicine / manufacturer labeling | Source revision: 6/2026
FARXIGA adult indication-specific renal instructions.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v6.1.
combination product scope
Do not borrow a single-agent SGLT2 renal threshold for a combination
This fixed combination includes saxagliptin and metformin. Its selected label version has a product-specific renal restriction; a lower threshold for a different dapagliflozin indication does not override it.
What to reconcileConfirm every ingredient, current combination label, indication and initiation versus continuation decision. The locally retained QTERNMET XR source is dated May 2019, not a current-label attestation.
1 source identities and dates
GlobalRPh RX List - QTERNMET XRGlobalRPh-hosted RX List | Source revision: May 2019
Adults with type 2 diabetes; fixed dapagliflozin/saxagliptin/metformin extended-release tablets, not the separate agents.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v3.5.
renal boundary and dialysis protocol difference
Do not merge label and higher-dose institutional dialysis protocols
The label includes CrCl exactly 30 in its >=30 band. UCSF prints >30 and <30, omitting exactly 30, and uses higher doses and different HD scheduling.
What to reconcileKeep source-specific dose, interval, indication, weight basis and modality together. The official threshold is explicit; seek institutional clarification rather than silently changing its headings.
3 source identities and dates
GlobalRPh RX List - CUBICIN RFGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Adult intravenous daptomycin. Product preparation, infection indication and institution-specific higher-dose regimens must remain separately attributed.
Read this stored source Daptomycin for injection - Fresenius Kabi USA 500 mg vialDailyMed / Fresenius Kabi USA, LLC | Source revision: 5/2022
Adult intravenous daptomycin. Product preparation, infection indication and institution-specific higher-dose regimens must remain separately attributed.
Read this stored source UCSF daptomycin - adult dosing guidanceUCSF Infectious Diseases Management Program | Source revision: Source revision date not established in selected retrieval.
Adult intravenous daptomycin. Product preparation, infection indication and institution-specific higher-dose regimens must remain separately attributed.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v6.0.
guideline vs label
NIH chronic-HD exception differs from RX restriction
The RX source does not recommend the combination below CrCl 30. The NIH panel separately permits the chronic-HD setting and describes uncertainty outside that setting.
What to reconcileReview the NIH row and applicable current label with an HIV specialist. This is a documented difference, not agreement between independent validators.
2 source identities and dates
GlobalRPh RX List - SymtuzaGlobalRPh-hosted RX List | Source revision: Revision date not established in selected retrieval.
Fixed combination; selected adult renal guidance. Do not substitute single-component TAF guidance.
Read this stored source NIH HIV renal table - SYMTUZANIH ClinicalInfo HIV Guidelines | Source revision: Revision date not established in selected retrieval.
Adult SYMTUZA fixed combination; panel recommendations, including explicitly identified uncertainty.
Read this stored source Source difference identified; final patient-specific adjudication required. Added: vearlier.
toxicity trigger versus renal dose band
A serum-creatinine cycle-hold trigger is not a clearance cutoff
Selected IV sources agree on unstudied pre-existing renal impairment and a subsequent-cycle toxicity hold at serum creatinine >=2 mg/dL.
What to reconcileDo not derive a CrCl threshold or transfer this instruction to oral decitabine/cedazuridine.
2 source identities and dates
GlobalRPh RX List - DACOGENGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Single-agent IV decitabine for labeled MDS regimens; not oral decitabine/cedazuridine (INQOVI). Exact preparation remains product-specific.
Read this stored source Decitabine for injection - Accord Healthcare 50 mg single-dose vialDailyMed / Accord Healthcare Inc. | Source revision: 9/2023
Single-agent IV decitabine for labeled MDS regimens; not oral decitabine/cedazuridine (INQOVI). Exact preparation remains product-specific.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v6.0.
dated label and multiple adjustment context
Distinguish initial renal reduction from treatment-emergent injury
The mirror and dated manufacturer PDF agree on selected baseline restrictions. Subsequent injury actions depend on indication and age.
What to reconcileKeep EXJADE separate from JADENU. Reconcile current labeling and assess glomerular/tubular injury rather than applying the starting-dose reduction to every situation.
2 source identities and dates
GlobalRPh RX List - EXJADEGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
EXJADE tablets dispersed for oral administration; indication- and age-specific iron chelation. Not a mg-for-mg JADENU regimen.
Read this stored source Deferasirox - EXJADE tablets for oral suspensionNovartis Pharmaceuticals Corporation / manufacturer prescribing information | Source revision: 7/2020
EXJADE tablets dispersed for oral administration; indication- and age-specific iron chelation. Not a mg-for-mg JADENU regimen.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v6.0.
qualitative restriction and removal only
Qualitative low-end dosing does not override severe-renal contraindication
The selected sources contraindicate severe renal disease/anuria but also advise low-end dosing in renal impairment. Dialyzability is described in overdose management.
What to reconcileDo not invent a numerical severity boundary or a dialysis supplement. Specialist off-label aluminum regimens are not adjudicated here.
2 source identities and dates
GlobalRPh RX List - DESFERALGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
DESFERAL injection in its labeled iron-intoxication/iron-overload context; not a newly constructed aluminum-overload dialysis regimen.
Read this stored source Deferoxamine - DESFERAL injectionNovartis Pharmaceuticals Corporation / manufacturer prescribing information | Source revision: 9/2022
DESFERAL injection in its labeled iron-intoxication/iron-overload context; not a newly constructed aluminum-overload dialysis regimen.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v6.0.
formulation and vehicle
Vehicle accumulation remains part of the IV decision
A reduced IV amount does not remove the SBECD precaution.
What to reconcileKeep renal monitoring, oral-switch consideration and the below-15 restriction attached.
2 source identities and dates
GlobalRPh RX List - BAXDELA IVGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Adult intravenous BAXDELA for labeled ABSSSI or CABP. Every dose is infused over 60 minutes.
Read this stored source DailyMed / BAXDELA IV exact product labelDailyMed / Melinta Therapeutics, LLC | Source revision: 6/2021
Adult intravenous BAXDELA for labeled ABSSSI or CABP. Every dose is infused over 60 minutes.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.6.
formulation and renal measure
An IV reduction is not an oral tablet dose
The two BAXDELA routes have different severe-renal instructions.
What to reconcileMatch route, indexed source measure and infection duration.
2 source identities and dates
GlobalRPh RX List - BAXDELA tabletsGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Adult oral BAXDELA for labeled bacterial skin infections or community-acquired bacterial pneumonia; not the IV formulation.
Read this stored source DailyMed / BAXDELA tablets exact product labelDailyMed / Melinta Therapeutics, LLC | Source revision: 6/2021
Adult oral BAXDELA for labeled bacterial skin infections or community-acquired bacterial pneumonia; not the IV formulation.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.6.
monitoring scope
PROLIA: no adjustment does not mean routine-risk treatment
Both retrieved sources contain advanced-CKD hypocalcemia precautions. This is not a disagreement or a missing-warning claim. Dose unchanged and CKD-MBD safety assessment are different questions.
What to reconcileComplete the advanced-CKD assessment and monitoring plan with appropriate expertise; do not substitute the nonadvanced-CKD monitoring interval.
2 source identities and dates
GlobalRPh RX List - PROLIAGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Denosumab - PROLIA subcutaneous injection; selected renal passages, not a complete prescribing monograph.
Read this stored source PROLIA - official advanced-CKD safety checkDailyMed / Amgen, Inc | Source revision: Prescribing information revised June 2026.
PROLIA - official advanced-CKD safety check; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.0.
qualified no adjustment and monitoring
No renal dose adjustment does not remove advanced-CKD safeguards
Selected mirror and June 2026 label paragraphs agree. Advanced-CKD calcium surveillance differs from the nonadvanced-CKD 10-14-day instruction.
What to reconcileReview CKD-MBD and the advanced-CKD monitoring plan before using the no-adjustment statement.
2 source identities and dates
GlobalRPh RX List - PROLIAGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
PROLIA for its labeled bone indications; not an XGEVA or biosimilar dosing substitution.
Read this stored source Denosumab - PROLIA subcutaneous injectionDailyMed / Amgen Inc. | Source revision: 6/2026
PROLIA for its labeled bone indications; not an XGEVA or biosimilar dosing substitution.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v6.0.
boundary units
IPRIVASK: exact-31 boundary and indexed clearance heading remain unresolved
The returned inequalities leave exactly 31 outside both bands, and the heading is indexed CrCl rather than eGFR. Neither issue is silently repaired.
What to reconcileObtain a reconciled authoritative table and renal-method assessment before relying on the ambiguous boundary. This card does not select a dose there.
1 source identities and dates
GlobalRPh RX List - IPRIVASKGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
IPRIVASK subcutaneous prophylaxis after elective hip replacement in the retrieved label; current marketing availability not verified.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.4.
formulation and contraindication scope
A labeled renal contraindication is not a reduced-dose suggestion
Both selected sources contraindicate CrCl below 50. The official injection source specifies Cockcroft-Gault and preserves sodium/fluid precautions.
What to reconcileConfirm the injectable product, indication, contraindicated medicines and sodium/volume status. This record does not adjudicate specialist off-label uremic bleeding.
2 source identities and dates
GlobalRPh RX List - DDAVP injectionGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
DDAVP 4 mcg/mL injection, IV or SC according to its indication; selected labeled DI/hemophilia A/type I vWD context, not a uremic-bleeding protocol.
Read this stored source Desmopressin - DDAVP injectionDailyMed / Ferring Pharmaceuticals Inc. | Source revision: 7/2022
DDAVP 4 mcg/mL injection, IV or SC according to its indication; selected labeled DI/hemophilia A/type I vWD context, not a uremic-bleeding protocol.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v6.0.